ASX Archives - Page 8 of 27 - Telix Pharmaceuticals Limited

Telix Files Form 20-F Registration Statement for Nasdaq ADS

Telix announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with the United States (U.S.) Securities and Exchange Commission (SEC) relating to a proposed listing of American Depository Shares (ADS), representing the Company’s ordinary shares, on the Nasdaq Stock Market (Nasdaq).

Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M

Telix today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3 2024).

Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform

Telix and RLS (USA) Inc., America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals, today announced an agreement by the Company to acquire RLS from its parent company, RLS Group Ltd. The acquisition significantly expands Telix’s North American manufacturing footprint and establishes the basis of a next generation radiometal production network to benefit Telix and select strategic commercial partners.

IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances

Telix today announces that the Company’s IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma (GBM), the most common and aggressive form of primary brain cancer.

Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2] agent for the characterisation of progressive or recurrent glioma (brain cancer) from treatment related changes in both adult and pediatric patients.

Telix Announces Reorganisation to Deliver on Strategic Priorities

Telix today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncology.

Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities

Telix today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise stated.

Telix Half-Year Results 2024 Investor Webcast Notification

Telix today advises that it will release its financial results for the half-year ended 30 June 2024 on Thursday 22 August 2024.

Telix Successfully Prices A$650 Million Convertible Bonds

Telix is pleased to announce that it has successfully priced A$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as “convertible bonds” (Convertible Bonds), are convertible into fully paid ordinary shares in Telix (Ordinary Shares). The Offering received strong support from eligible investors globally.

Q2 2024 Revenue and Business Highlights, Guidance Upgrade

Telix today provides an update on its revenue and operational performance for the quarter ended 30 June 2024 (Q2 2024).